Logo

Apexigen Presents Results of Sotigalimab + Pembrolizumab in P-II Trial for the Treatment of Metastatic Melanoma at AACR 2022

Share this

Apexigen Presents Results of Sotigalimab + Pembrolizumab in P-II Trial for the Treatment of Metastatic Melanoma at AACR 2022

Shots:

  • The P-II trial evaluates sotigalimab + pembrolizumab in patients with advanced or metastatic melanoma. The combination induced broad innate & adaptive immune activation in local & distant tumors
  • The results showed ORR (50% & 55%) at the RP2D of sotiga (10mg), DCR (67%), CR rate (17%), PR (33%) & SD (17%), clinical responses were seen in patients with PD-L1- tumors & with elevated LDH. The combination demonstrated an encouraging anti-tumor activity, upregulation of genes associated with APC & T cells, increase in T cell infiltration & clonality in both tumor sites
  • The combination was well-tolerated, 6 patients experienced grade 3 immune-mediated AEs with no dose-limiting toxicities and no discontinuations or deaths

Ref: Globe Newswire | Image: Apexigen

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions